Table 3 Adverse events in neoadjuvant therapy and surgery
From: Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
Type of event | No. of patients | |
|---|---|---|
All grades (%) | Grade ≥ 3 (%) | |
Adverse event (n = 47) | 47 (100.0) | 3 (6.4) |
Diarrhea | 37 (78.7) | 1 (2.1) |
Rash | 37 (78.7) | 0 (0.0) |
Stomatitis | 32 (68.1) | 0 (0.0) |
Paronychia | 24 (51.1) | 0 (0.0) |
Anorexia and nausea | 12 (25.5) | 0 (0.0) |
Fatigue | 11 (23.4) | 0 (0.0) |
Pruritus | 10 (21.3) | 0 (0.0) |
Dry skin | 4 (8.5) | 0 (0.0) |
Interstitial pneumonia | 3 (6.4) | 1 (2.1) |
Elevated ALT | 3 (6.4) | 1 (2.1) |
Surgical-related complications (n = 33) | ||
Prolonged air leakage | 3 (9.1) | 0 (0.0) |
Bronchopleural fistula | 1 (3.0) | 0 (0.0) |
